anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a smoke-free moxa stick and belongs to the field of drugs for moxibustion. The moxa stick is prepared from raw materials in parts by weight as follows: 150-200 parts of moxa carbon, 5-10 parts of common bletilla pseudobulb and 5-10 parts of glutinous rice; a preparation method of the moxa carbon comprises steps as follows: dried moxa leaves are calcined into carbon and ground into fine powder. The smoke-free moxa stick adopts a scientific and reasonable formula, all medicines are combined, and the effects of warming meridians, promoting qi circulation and relieving pain are improved. The smoke-free moxa stick has a remarkable effect on treating diseases caused by wind cold dampness and blood stasis and has the effective rate up to 96% or higher. Addition of chemical binders is not required in the production process, and the smoke-free moxa stick reaches a smoke-free state during usage and is non-toxic, harmless and environment-friendly, and the problems of chemical pollution and damage are solved. The smoke-free moxa stick is convenient to prepare, simple to use, low in cost and suitable for wide popularization.
The objective of this case study is to report on the diagnosis and treatment of medication-related osteonecrosis of the jaw (MRONJ), which was originally misdiagnosed and mistreated as endodontic disease. A patient was referred for worsening odontalgia despite root canal therapy on tooth No. 19 and a course of oral antibiotics. Examination demonstrated slight buccal swelling and tenderness in the left masseter and a 7-mm diameter area of exposed bone on the mandibular left lingual torus. Further history-taking revealed prior bisphosphonate therapy for metastatic breast cancer. MRONJ was identified as the likely diagnosis, and the patient was appropriately referred to oral and maxillofacial surgery where the diagnosis was confirmed and surgical debridement performed. The case study demonstrates how the symptomatology and presentation of MRONJ can resemble endodontic disease and that timely and appropriate treatment requires eliciting an in-depth medical history, reaching a complete pulpal and periapical diagnosis, and remaining attentive to the presence of exposed bone on examination.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder affecting people worldwide. It is characterized by several key features, including hyperinsulinemia, hyperglycemia, hyperlipidemia, and dysbiosis. Epidemiologic studies have shown that T2DM is closely associated with the development and progression of cancer. T2DM-related hyperinsulinemia, hyperglycemia, and hyperlipidemia contribute to cancer progression through complex signaling pathways. These factors increase drug resistance, apoptosis resistance, and the migration, invasion, and proliferation of cancer cells. Here, we will focus on the role of hyperinsulinemia, hyperglycemia, and hyperlipidemia associated with T2DM in cancer development. Additionally, we will elucidate the potential molecular mechanisms underlying their effects on cancer progression. We aim to identify potential therapeutic targets for T2DM-related malignancies and explore relevant directions for future investigation.
The control group will receive a new 24G or 22G short peripheral venous catheter for puncture using direct view aseptic technique, while the intervention group will be implanted with a new long peripheral venous catheter selected by the puncture operator using aseptic technique depending on the puncture location and venous conditions. After successful puncture, blood was returned in both groups and easily washed with 0.9% sodium chloride solution. The catheter was considered to be placed in the correct position and could be used normally. Intravenous infusion therapy should be started immediately after successful catheterization. The catheter should be checked at least 3 times a day and washed with 10 ml.9% sodium chloride solution before each intravenous therapy. After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Patient information was collected during the study, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.
In cystic fibrosis (CF), impaired mucociliary clearance leads to chronic infection and inflammation. However, cilia beating features in a CF altered environment, consisting of dehydrated airway surface liquid layer and abnormal mucus, have not been fully characterized. Furthermore, acute inflammation is normally followed by an active resolution phase requiring specialized proresolving lipid mediators (SPMs) and allowing return to homeostasis. However, altered SPMs biosynthesis has been reported in CF. Here, we explored cilia beating dynamics in CF airways primary cultures and its response to the SPMs, resolvin E1 (RvE1) and lipoxin B4 (LXB4). Human nasal epithelial cells (hNECs) from CF and non-CF donors were grown at air-liquid interface. The ciliary beat frequency, synchronization, orientation, and density were analyzed from high-speed video microscopy using a multiscale Differential Dynamic Microscopy algorithm and an in-house developed method. Mucins and ASL layer height were studied by qRT-PCR and confocal microscopy. Principal component analysis showed that CF and non-CF hNEC had distinct cilia beating phenotypes, which was mostly explained by differences in cilia beat organization rather than frequency. Exposure to RvE1 (10 nM) and to LXB4 (10 nM) restored a non-CF-like cilia beating phenotype. Furthermore, RvE1 increased the airway surface liquid (ASL) layer height and reduced the mucin MUC5AC thickness. The calcium-activated chloride channel, TMEM16A, was involved in the RvE1 effect on cilia beating, hydration, and mucus. Altogether, our results provide evidence for defective cilia beating in CF airway epithelium and a role of RvE1 and LXB4 to restore the main epithelial functions involved in the mucociliary clearance.
In the field of sports, there is a lot of knowledge about sports injuries, nutrition and regeneration. Much less is known about mental health among athletes. The investigators often think that the incidence of mental problems is low among top athletes. As the main cause of this misconception, the authors attribute the idealization of sports and athletes. Both the professional and the lay public are often of the opinion that only mentally strong individuals can be successful, which of course means that there is no place in the highest level for individuals with mental problems and disorders.

The clinical study will be performed with 400-500 athletes of both genders aged 18 to 40, from Slovenia. The investigators will invite all athletes who have been categorized in the current year and classified into the membership category, i.e. national, international, world or Olympic class (there were 500 at the last categorization) and they compete in various sports disciplines. The study will be designed as a cross-sectional study. For the purpose of the research, the investigators will use a battery of psychodiagnostic questionnaires consisting of five parts: demographics and sport characteristic, depression symptomatic, anxiety symptomatic, eating problems, alcohol use and abuse and resilience characteristics of individual athlete.
A method of collecting participant replies into a database residing on computing devices. The participant replies provide information of particular interest about the participant. The replies are provided in response to questions selected by an overseer. The questions are grouped into question sets; each question set addressing a particular aspect of information being sought. The question sets are further grouped into lists of the question sets determined by an overseer in accordance with the participant replies, wherein each participant is assigned a list. The invention establishes data paths over communication networks for communicating the questions and replies. For each participant a next question in the list is determined based on the participant's previous replies. The determined next question is communicated to the participant via the data path and the replies are communicated back from the participant via the data path. After all the questions on the list are asked a report is created and forwarded to the overseer who may change the make up of the list of question sets for the participant.
Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
All persons aged 18 - 44 years planning to travel alone and attending the travel clinic of the Medical Outpatient Clinic in Lausanne will be asked to participate. The subjects will be randomized into three groups: 1. no intervention, 2. free condoms without further explanations, 3. a structured intervention of 5 minutes on STI risk reduction plus free condoms. The structured interventions will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The subjects will complete a pre-travel questionnaire prior to the medical consultation. A post-travel questionnaire will be sent to them 10 days after their trip. The questionnaires will include questions on demographic characteristics, sexual habits, alcohol/tobacco/marijuana consumption and sexual relationships during the trip.
A wristband biosensing system, a wristband biosensing apparatus and a biological sensing method. The wristband biosensing system includes a wristband body, at least one physiological signal sensor, at least one deformation sensor, and a processing device. The wristband body is worn on a wrist of a user. The at least one physiological signal sensor is disposed at a position on the wristband body corresponding to at least one sensing portion of the wrist, and configured to detect a physiological signal of each sensing portion. The at least one deformation sensor is disposed around each physiological signal sensor, and configured to detect deformation of each sensing portion and output a deformation signal. The processing device is coupled to the physiological signal sensor and the deformation sensor, and configured to receive the physiological signal and the deformation signal, inquire a compensation signal corresponding to the deformation signal, and correct the physiological signal using the compensation signal, so as to output a corrected physiological signal of each sensing portion.
Concomitant use of buprenorphine and benzodiazepines or other CNS depressants increases the risk of adverse reactions including overdose and death. Medication-assisted treatment of opioid use disorder, however, should not be categorically denied to patients taking these drugs. Prohibiting or creating barriers to treatment can pose an even greater risk of morbidity and mortality due to the opioid use disorder alone.

As a routine part of orientation to buprenorphine treatment, educate patients about the risks of concomitant use of benzodiazepines, sedatives, opioid analgesics, and alcohol.

Develop strategies to manage use of prescribed or illicit benzodiazepines or other CNS depressants at initiation of buprenorphine treatment, or if it emerges as a concern during treatment. Adjustments to induction procedures and additional monitoring may be required. There is no evidence to support dose limitations or arbitrary caps of buprenorphine as a strategy to address benzodiazepine use in buprenorphine-treated patients. However, if a patient is sedated at the time of buprenorphine dosing, delay or omit the buprenorphine dose if appropriate.

Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.

For patients in buprenorphine treatment, benzodiazepines are not the treatment of choice for anxiety or insomnia. Before co-prescribing benzodiazepines, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments to address anxiety or insomnia. Ensure that other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of the patient's buprenorphine treatment and coordinate care to minimize the risks associated with concomitant use.

If concomitant use is warranted, strongly consider prescribing naloxone for the emergency treatment of opioid overdose, as is recommended for all patients in buprenorphine treatment for opioid use disorder [see Warnings and Precautions (5.2)]. 

In addition, take measures to confirm that patients are taking their medications as prescribed and are not diverting or supplementing with illicit drugs. Toxicology screening should test for prescribed and illicit benzodiazepines [see Drug Interactions (7)].
All consecutive patients referred for CTO PCI between August 2017 and July 2021 at Acibadem University Kocaeli Acibadem Hospital, Kocaeli; Erciyes University Medical Faculty, Kayseri; Istanbul University Cerrahpasa Medical Faculty, Haseki Cardiology Institute; Istanbul; Memorial Bahcelievler Hospital, Istanbul were screened for enrollment in the study. The exclusion criteria included: (a) any acute coronary syndrome within 3 months; (b) severe heart failure issues; (c)severe renal failure (d) failure to provide written informed consent.The radial access group consisted of patients with single or bi-radial approach. Any femoral artery puncture was considered a femoral case. For example, a crossover from any radial to femoral access was considered a femoral case. Procedures were performed by 4 interventional cardiologists, who are dedicated radial operators, at 4 different centers. The protocol was approved by the institutional review board and all patients provided written informed consent.
The present invention relates to oral liquid for clearing livers and gallbladders, which belongs to the field of traditional Chinese medicines. The oral liquid for clearing livers and gallbladders is prepared from pure Chinese herbal medicines such as bear gall powder, tree peony bark, barbed skullcap herb, pilose asiabell root, Chinese angelica root, glossy privet fruit, Chinese eaglewood and malt according to a traditional Chinese medicine preparation process. The oral liquid for clearing livers and gallbladders is a pure traditional Chinese medicine preparation. The present invention has the advantages of no toxic or side effect and conspicuous curative effect. Through the combination of the medicines, the oral liquid for clearing livers and gallbladders is warm but not dry and is cool but not cold so as to accord with the pathological basis of long-lasting chronic hepatitis, namely that if damp heat and excess evil are not thoroughly solved, livers and kidneys has the deficiency of qi and blood. Therefore, the present invention has the efficiency of dredging liners, promoting the function of gallbladders, supplementing livers, tonifying kidneys and strengthening body resistance to dispel evil.
Neurontin is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.

Patients >12 years of age: The effective dose of Neurontin is 900 to 1800 mg/day and given in divided doses (three times a day) using 300 or 400 mg capsules, or 600 or 800 mg tablets. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules, or 600 or 800 mg tablets three times a day up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours. 

Pediatric Patients Age 3–12 years: The starting dose should range from 10–15 mg/kg/day in 3 divided doses, and the effective dose reached by upward titration over a period of approximately 3 days. The effective dose of Neurontin in patients 5 years of age and older is 25–35 mg/kg/day and given in divided doses (three times a day). The effective dose in pediatric patients ages 3 and 4 years is 40 mg/kg/day and given in divided doses (three times a day) (see  CLINICAL PHARMACOLOGY, Pediatrics.) Neurontin may be administered as the oral solution, capsule, or tablet, or using combinations of these formulations. Dosages up to 50 mg/kg/day have been well-tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours. 

It is not necessary to monitor gabapentin plasma concentrations to optimize Neurontin therapy. Further, because there are no significant pharmacokinetic interactions among Neurontin and other commonly used antiepileptic drugs, the addition of Neurontin does not alter the plasma levels of these drugs appreciably.

If Neurontin is discontinued and/or an alternate anticonvulsant medication is added to the therapy, this should be done gradually over a minimum of 1 week.
1. Uterine fibroids Uterine leiomyomas or fibroids are one of the most common conditions affecting women of reproductive age. They account for approximately a third of all hysterectomies performed. Symptoms often attributed to uterine leiomyomas include excessive menstrual bleeding, dysmenorrhea, pelvic pain, and so called "bulk symptoms," or symptoms related to pressure on adjacent organs such as ureteral obstruction, urinary frequency and urgency, rectal pressure, pelvic pressure and increasing abdominal girth. Current treatment for symptomatic uterine fibroids includes hysterectomy, myomectomy and uterine fibroid embolization.
2. Lower urinary tract symptoms Although, urinary symptoms like frequency, urgency, incontinence, and voiding dysfunction are often attributed to fibroids, the relationship between fibroids and lower urinary tract symptoms (LUTS) has been poorly studied. The public health burden of fibroids has been studied before and after radical hysterectomy, supracervical hysterectomy, and total abdominal hysterectomy.(1-3) What is missing in the literature is a comparison of traditional and non-traditional surgical fibroid techniques in a prospective fashion. Moreover, there are no studies evaluating the relationship between anatomic factors like uterine size or fibroid number or location and the presence of LUTS.
The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
FIELD: medicine, veterinary science. SUBSTANCE: invention relates to a medicinal preparation for external use and can be used for treatment of infected surface and deep wounds, burns and skin and mucosa inflammatory diseases. Medicinal preparation has 1-deoxy-1-N-[methyl-(2-acridone-9-one-10-yl-acetate)] -ammonium-D-glucidol as an active component, 1,2-propylene glycol as a base and catapol as a preserving agent additionally taken in the definite ratio of components. Invention provides preparing the preparation with high biological availability, stability of its medicinal form at storage and ensuring to carry out the effective treatment of infected surfaces including hard to reach cavities of body. EFFECT: enhanced effectiveness of preparation, valuable medicinal properties. 6 tbl, 4 ex
A method and system for the relief from side effects associated with the consumption of cannabis, cannabis extracts, cannabis products, or isolated or synthetic forms thereof. The apparatus comprising a sealed vessel for containing the composition, which may be in the form of a liquid, powder, tablet, topical lotion, tincture, or pressurized vapor. In some embodiments, the container is designed to be easily accessible to those under the influence of THC, provides evidence of prior use or tampering, includes child and/or pet safety measures, or other security considerations. In some embodiments, the composition may be inhaled, drunk, swallowed, or administered sublingually, topically, transdermal, oracularly, nasally, peroral, transmucosal, injection or nanoneedle, for example. In some embodiments, the composition may be designed to provide relief from the side effects of a cultivar of cannabis (e.g. Charlotte's Web, Northern Lights, etc.). In some embodiments, the composition and apparatus are sold as a kit along with various other cannabis side effect remedies, or cannabis, or a cannabis product.
Amyotrophic lateral sclerosis (ALS) represents a rare and potentially fatal neurodegenerative disease. Diverse T-cell subsets could potentially exert diametrically opposite impacts upon ALS development. A two-sample Mendelian randomization (MR) analysis was performed to investigate the correlation between 244 T-cell subsets and ALS risk. Genetic instrumental variables were procured from a standard genome-wide association study (GWAS) that encompassed 244 T-cell subsets in 3757 individuals of European lineage. ALS-related data were collected from a GWAS comprising 20,806 ALS instances and 59,804 European control participants. Multiple sensitivity analyses were performed to verify the robustness of the significant results. Reverse MR analysis was used for delineating the effects of ALS on the characteristics of T-cells. After multiple comparison corrections, 24 out of the 244 subtypes demonstrated a potential association with ALS risk. Significantly, 75% of these associations encompassed the expression of the CD3 on diverse T-cell subtypes, revealing a highly consistent inverse relation to ALS risk. The proportion of T regulatory cells (Tregs) in CD4+ T cells and secreting Tregs in CD4+ T cells demonstrated negative associations with the risk of ALS. CCR7 expression on naive CD4+ T cells and CCR7 expression on naive CD8+ T cells showed positive associations with ALS risk. Certain T-cell subsets, particularly those identified by CD3 expression on terminally differentiated CD8+ T cells, proportions of Tregs, and CCR7 expression, indicated an association with ALS risk. These findings harmonize with and extend previous observational studies investigating the involvement of T lymphocyte subset-induced immunological processes in ALS.
Verticillium wilt (VW) is an important and widespread disease of cotton and once established is long-lived and difficult to manage. In Australia, the non-defoliating pathotype of Verticillium dahliae is the most common, and extremely virulent. Breeding cotton varieties with increased VW resistance is the most economical and effective method of controlling this disease and is greatly aided by understanding the genetics of resistance. This study aimed to investigate VW resistance in 240 F7 recombinant inbred lines (RIL) derived from a cross between MCU-5, which has good resistance, and Siokra 1-4, which is susceptible. Using a controlled environment bioassay, we found that resistance based on plant survival or shoot biomass was complex but with major contributions from chromosomes D03 and D09, with genomic prediction analysis estimating a prediction accuracy of 0.73 based on survival scores compared to 0.36 for shoot biomass. Transcriptome analysis of MCU-5 and Siokra 1-4 roots uninfected or infected with V. dahliae revealed that the two cultivars displayed very different root transcriptomes and responded differently to V. dahliae infection. Ninety-nine differentially expressed genes were located in the two mapped resistance regions and so are potential candidates for further identifying the genes responsible for VW resistance.